[
  {
    "ts": null,
    "headline": "What Is the Intent Behind AbbVie's Recent Acquisition Spree?",
    "summary": "ABBV's $1.2B neuroscience deal and 30+ acquisitions highlight its push to expand beyond immunology into obesity, oncology and brain health.",
    "url": "https://finnhub.io/api/news?id=eb09f7dbdfaa9734efc1d66217ea368d21397abd4e2c31f020e5200ae80b5436",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756307820,
      "headline": "What Is the Intent Behind AbbVie's Recent Acquisition Spree?",
      "id": 136539545,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV's $1.2B neuroscience deal and 30+ acquisitions highlight its push to expand beyond immunology into obesity, oncology and brain health.",
      "url": "https://finnhub.io/api/news?id=eb09f7dbdfaa9734efc1d66217ea368d21397abd4e2c31f020e5200ae80b5436"
    }
  },
  {
    "ts": null,
    "headline": "Best Dividend Aristocrats For September 2025",
    "summary": "Discover top Dividend Aristocrats for 2025! Explore undervalued picks with 10%+ annualized returns, robust payout growth, and reliable income opportunities.",
    "url": "https://finnhub.io/api/news?id=6fa72cb3c60dde4a3180ad17c2df91d58aa59ccc934dd1f72334c03464c353e0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756303789,
      "headline": "Best Dividend Aristocrats For September 2025",
      "id": 136539374,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1962656730/image_1962656730.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Discover top Dividend Aristocrats for 2025! Explore undervalued picks with 10%+ annualized returns, robust payout growth, and reliable income opportunities.",
      "url": "https://finnhub.io/api/news?id=6fa72cb3c60dde4a3180ad17c2df91d58aa59ccc934dd1f72334c03464c353e0"
    }
  },
  {
    "ts": null,
    "headline": "RINVOQ速 (upadacitinib) Receives Health Canada Notice of Compliance (NOC) for Giant Cell Arteritis in adults",
    "summary": "AbbVie today announced that Health Canada has issued a Notice of Compliance for RINVOQ速 (upadacitinib) for the treatment of adults with giant cell arteritis (GCA), both used in combination with a tapering course of corticosteroids and as monotherapy following discontinuation of corticosteroids.4",
    "url": "https://finnhub.io/api/news?id=b87d549fed82b56478f63873572514fbb5cd403db2012f361dbe29c16e8c0fd3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756296000,
      "headline": "RINVOQ速 (upadacitinib) Receives Health Canada Notice of Compliance (NOC) for Giant Cell Arteritis in adults",
      "id": 136536357,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie today announced that Health Canada has issued a Notice of Compliance for RINVOQ速 (upadacitinib) for the treatment of adults with giant cell arteritis (GCA), both used in combination with a tapering course of corticosteroids and as monotherapy following discontinuation of corticosteroids.4",
      "url": "https://finnhub.io/api/news?id=b87d549fed82b56478f63873572514fbb5cd403db2012f361dbe29c16e8c0fd3"
    }
  },
  {
    "ts": null,
    "headline": "BIGY: Targeted 12% Distribution With Options Strategy",
    "summary": "Read the latest analysis on the YieldMax Target 12 Big 50 Option Income ETF: A diversified large-cap covered call strategy targeting a 12% yield.",
    "url": "https://finnhub.io/api/news?id=f76284fee80ba98bfb1a081074b616dcd526f8edf46d4541eb029fa9f5473fde",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756291484,
      "headline": "BIGY: Targeted 12% Distribution With Options Strategy",
      "id": 136537105,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2162129137/image_2162129137.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Read the latest analysis on the YieldMax Target 12 Big 50 Option Income ETF: A diversified large-cap covered call strategy targeting a 12% yield.",
      "url": "https://finnhub.io/api/news?id=f76284fee80ba98bfb1a081074b616dcd526f8edf46d4541eb029fa9f5473fde"
    }
  },
  {
    "ts": null,
    "headline": "Dyslipidemia Market Research Report 2025-2035 | Competitive Analysis of Amgen, Sanofi, Regeneron, Pfizer, Novartis, Viatris, AbbVie, AstraZeneca, Horizon Therapeutics, Esperion Therapeutic",
    "summary": "Dyslipidemia, linked to elevated cardiovascular disease risk, is benefiting from advancements in lipid profiling and genetic testing, catalyzing demand for personalized treatments. Statins dominate therapy, supported by PCSK9 inhibitors and RNA-based medicines. However, challenges like medication non-compliance, side effects, and high drug costs, especially in lower-income regions, impede market expansion. Yet, proactive government initiatives and heightened research funding are improving treatm",
    "url": "https://finnhub.io/api/news?id=459030ebf78534849e2c06f68d0a59a57cd09453cecbb0b13f1d5e1fe019216b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756285140,
      "headline": "Dyslipidemia Market Research Report 2025-2035 | Competitive Analysis of Amgen, Sanofi, Regeneron, Pfizer, Novartis, Viatris, AbbVie, AstraZeneca, Horizon Therapeutics, Esperion Therapeutic",
      "id": 136536358,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Dyslipidemia, linked to elevated cardiovascular disease risk, is benefiting from advancements in lipid profiling and genetic testing, catalyzing demand for personalized treatments. Statins dominate therapy, supported by PCSK9 inhibitors and RNA-based medicines. However, challenges like medication non-compliance, side effects, and high drug costs, especially in lower-income regions, impede market expansion. Yet, proactive government initiatives and heightened research funding are improving treatm",
      "url": "https://finnhub.io/api/news?id=459030ebf78534849e2c06f68d0a59a57cd09453cecbb0b13f1d5e1fe019216b"
    }
  }
]